

Not for distribution or release in the United States



# Investor Presentation



For personal use only

May 2025



# Disclaimer and important notice

This presentation has been prepared by TruScreen Group Limited (TRU). This presentation has been prepared in relation to the offer of new shares in TRU (New Shares) by way of a:

- Placement to selected investors in certain jurisdictions (Placement); and
- Share Purchase Plan to TRU's eligible existing shareholders with an address in either New Zealand or Australia (SPP),

under clause 19 of Schedule 1 of the Financial Markets Conduct Act 2013 (FMCA) in New Zealand and in accordance with the relief granted in Australian Securities and Investments Commission (ASIC) Instrument 23-0122 and ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 as amended by ASIC Instrument 25-0323 in Australia (together, the Offer).

## Information of a general nature:

This presentation contains summary information about TRU and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in TRU or that would be required in a product disclosure statement for the purposes of the FMCA or a prospectus or other disclosure document for the purposes of Chapter 6D of the Australian Corporations Act 2001 (Cth) ("Australian Corporations Act"). The historical information in this presentation is, or is based upon, information that has been released to NZX Limited (NZX) and ASX Limited (ASX). This presentation should be read in conjunction with TRU's other periodic and continuous disclosure announcements, which are available at [www.nzx.com](http://www.nzx.com) and [www.asx.com.au](http://www.asx.com.au).

## NZX and ASX:

The New Shares will be quoted on the NZX Main Board following completion of each of the Placement and the Retail Offer, and an application will be made by TRU for the New Shares to be quoted on the ASX.

Neither NZX nor ASX accepts any responsibility for any statement in this presentation. NZX is a licensed market operator, and the NZX Main Board is a licensed market under the FMCA.

## Not financial product advice:

This presentation is for information purposes only and is not financial, investment or financial product advice or a recommendation to acquire TRU securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult a broker, solicitor, accountant and/or other professional adviser.

## Past performance:

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

## Future performance:

This presentation contains certain "forward-looking statements" such as indications of, and guidance on, future earnings and financial position and performance. Forward-looking statements can generally be identified by the use of forward-looking words such as 'projected', 'expect', 'anticipate', 'likely', 'intend', 'could', 'may', 'predict', 'plan', 'propose', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance' and other similar expressions within the meaning of securities laws of applicable jurisdictions, and include, but are not limited to future revenues, the timing of implementation of certain initiatives, growth strategies, the timetable of the Offer and the use of proceeds. The forward-looking statements contained in this presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of TRU, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not materially differ from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements, including the risk factors set out in this presentation. Investors should consider the forward-looking statements contained in this presentation in light of those disclosures.

# Disclaimer and important notice (continued)

## Future performance (continued):

The forward-looking statements are based on information available to TRU as at the date of this presentation. Except as required by law or regulation (including the NZX and ASX Listing Rules) TRU undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance on, future earnings or financial position or performance are also forward-looking statements. An investment in securities in TRU is subject to investment and other known and unknown risks, some of which are beyond the control of TRU. TRU does not guarantee any particular rate of return or the performance of TRU.

## Financial data:

All dollar values are in New Zealand dollars (NZ\$ or NZD) unless otherwise stated.

Investors should be aware that this presentation contains certain financial information and measures that are "non-GAAP financial information" under the New Zealand Financial Markets Authority Guidance Note on disclosing non-GAAP financial information, "non-IFRS financial information" under Regulatory Guide 230 on disclosing non-IFRS financial information published by ASIC and "non-GAAP financial measures" within the meaning of Regulation G, under the U.S. Securities Exchange Act of 1934, and, therefore, are not recognised under New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and International Financial Reporting Standards (IFRS). The disclosure of such non-IFRS/GAAP financial information and financial measures in the manner included in this Presentation would not be permissible in a registration statement under the U.S. Securities Act of 1933 (the U.S. Securities Act). The non-IFRS/non-GAAP financial information and financial measures do not have a standardised meaning prescribed by NZ IFRS, Australian Accounting Standards or IFRS, and therefore, may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with NZ IFRS or IFRS. Although TRU believes the non-IFRS/non-GAAP financial information and financial measures provide useful information to users in measuring the financial performance and condition of TRU, investors are cautioned not to place undue reliance on any non-IFRS/non-GAAP financial information or financial measures included in this presentation.

## Pro forma financial information:

This presentation also contains pro forma historical financial information to show the impact of the Placement. The pro forma information has not been audited or reviewed by TRU's auditors. The pro forma financial information provided in this presentation is for illustrative purposes only and is not represented as being indicative of TRU's views on its future financial condition and/or performance. The pro forma financial information has been prepared on the basis set out in this presentation. Investors should note that the pro forma financial information has not been prepared in accordance with, and does not purport to comply with, Article 11 of Regulation S-X under the U.S. Securities Act.

## Not a registered offer document:

This presentation is not a product disclosure statement, prospectus or other disclosure document under New Zealand law, Australian law, or any other law (and will not be lodged with the Registrar of Financial Service Providers, New Zealand Companies Office, ASIC or any other regulator or exchange in New Zealand, Australia or any other jurisdiction). Such regulators take no responsibility for the contents of this presentation. Accordingly, this presentation may not contain all information which a prospective investor may require to make a decision whether to subscribe for New Shares and it does not contain all of the information which would otherwise be required by New Zealand law, Australian law or any other law to be disclosed in a regulated product disclosure statement, prospectus, or any other form of disclosure document. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction, including the United States (and will not be lodged with the U.S. Securities Exchange Commission).

Any decision to purchase New Shares in the SPP should be made on the basis of the information to be contained in a separate offer document to be prepared and made available to eligible retail shareholders. The offer booklet for the SPP will be available to eligible retail shareholders in New Zealand and Australia following its lodgement with NZX and ASX. Any eligible shareholder who wishes to apply for New Shares under the SPP should review the offer booklet and apply in accordance with the instructions contained in the offer booklet or as otherwise communicated by TRU. This presentation does not constitute investment or financial advice (nor tax, accounting or legal advice) or any recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of New Shares. The release, publication or distribution of this presentation (including an electronic copy) in jurisdictions outside New Zealand and Australia may be restricted by law and you should observe such restrictions and should seek your own advice on such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws (see the Foreign Selling Restrictions section of this presentation).

By attending or reading this presentation you represent, warrant and agree that you: (i) are entitled to and permitted under applicable laws and regulations to receive the information contained in this presentation in accordance with the restrictions as set out in this section of the presentation; (ii) will base any investment decisions solely on information released by TRU via NZX and ASX (including, in the case of the SPP, the offer booklet for the SPP), and (iii) agree to be bound by the limitations contained therein.

# Disclaimer and important notice (continued)

## Distribution of presentation:

This presentation (including an electronic copy) must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by TRU of any law. The distribution of this presentation in other jurisdictions outside New Zealand or Australia may be restricted by law, and persons into whose possession this presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate applicable securities laws. None of TRU, any person named in this presentation or any of their affiliates accept or shall have any liability to any person in relation to the distribution or possession of this presentation from or in any jurisdiction.

## Not for distribution or release in the United States:

This presentation may not be released or distributed in the United States. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. The offer and sale of the New Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws of any state or other jurisdiction of the United States.

## Eligibility:

Determination of eligibility of investors for the purposes of the Offer (or any part of the Offer) is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of the underwriters and lead managers, and TRU. Each of the underwriters and lead managers and TRU and each of their respective related bodies corporate and affiliates, and each of their respective directors, officers, partners, employees, representatives and agents, disclaim any duty or liability in respect of that determination and the exercise or otherwise of that discretion, to the maximum extent permitted by law.

## Disclaimer:

To the maximum extent permitted by law, the lead managers, TRU, and their respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, for any direct or indirect expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and/or the information in this presentation being inaccurate or incomplete in any way for any reason, whether in tort (including negligence), arising under statute, in contract or equity or otherwise. To the maximum extent permitted by law, the underwriters and lead managers and their respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (Specified Persons) make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation and, with regards to each Specified Person, take no responsibility for any part of this presentation or the Offer. The Specified Persons make no recommendations as to whether you or your related parties should participate in the Offer nor do they make any representations or warranties to you concerning the Offer, and you represent, warrant and agree that you have not relied on any statements made by any of the Specified Persons in relation to the Offer and you further expressly disclaim that you are in a fiduciary relationship with any of them. You agree that you will not bring any proceedings against or hold or purport to hold any Specified Person liable in respect of this presentation or the information in this presentation and waive any rights you may otherwise have in this respect. Statements made in this presentation are made only as the date of this presentation. The information in this presentation remains subject to change without notice. TRU reserves the right to withdraw the Offer or vary the timetable for the Offer (whether for the Placement or the SPP) without notice.

## General:

For the purposes of this Disclaimer and Important Notice, "presentation" means the slides, any oral presentation of the slides by TRU, any question-and-answer session that follows that oral presentation, hard copies of this presentation and any materials distributed at, or in connection with, that presentation.



**Who is TruScreen**

**The TruScreen Technology**

**Why TruScreen**

**TruScreen Sales Strategy and Markets**

**TruScreen Highlights CY 24 – CY25**

**TruScreen Outlook: FY26 and Beyond**

**TruScreen Options Key Terms**



**NATIONAL MEDICAL PRODUCTS ADMINISTRATION**  
国家药品监督管理局



## Who is TruScreen



**Dual listed on the Australian (ASX) (foreign exempt listing) and New Zealand (NZX) stock exchanges, with a common ticker code of TRU.**



**TruScreen Group Ltd is a revenue generating Life Science company with FY25 annual sales of NZ\$ 1.7m, down from \$2.1m in FY24.** This lower result was largely due to delays in programs in Zimbabwe (delayed until FY26), Vietnam (launched April 2025), and delayed product registrations in Indonesia and Uzbekistan. Sales from these delayed commercial activities are expected to be realised in FY26.



**TruScreen Group Ltd expects FY26 sales to exceed NZ\$ 2.8m**



**NATIONAL MEDICAL PRODUCTS ADMINISTRATION**  
国家药品监督管理局



For personal use only

# Key Financials

As at 28 May 2025

**Market Cap:**  
**NZ \$16.09M**


**Share Price:**  
**AU\$0.027 / NZ\$0.029**

**Cash Balance (pro-forma):**  
**NZ\$365,000**

**Issued Capital: 554,907,719**

**Current Holders: 1942**

# TRU Price History (NZX)



# An Experienced Leadership Team



**Mr. Anthony Ho**

**B. Com (UNSW), CA, FAICD,  
FCIS, FGIA**

**Non-executive Chairman**

- **Currently a Director and Chairman of a number of listed ASX companies.**
- **Previous Executive Director of sales and distribution company Arthur Yates & Co Limited, as well as Finance Director/CFO of listed retailers on the ASX – M. S. McLeod Holdings Limited (Downtown Duty Free), Galore Group Limited (Barbeques Galore) and Brazin Limited (Bras N Things, Sanity Music).**
- **Prior to joining commerce, Tony was a partner of Cox Johnston & Co, Chartered Accountants which has since merged with Ernst & Young.**



**Mr. Christopher Horn**

**B. Com (UNSW), FCA**

**Non-executive Independent Director**

- **Involved with TruScreen for a number of years. He is an experienced business executive and has acted in a number of management roles including 20 years as a senior partner of KPMG and its predecessor firms.**
- **Director of a number of private companies across a broad range of business activities including corporate advisory, financial services, and funds management.**
- **Commerce graduate from the University of New South Wales, Sydney, Australia and a Fellow of the Institute of Chartered Accountants in Australia and New Zealand. Chris is also the Chair of TruScreen's Audit, Finance and Risk Committee.**

# An Experienced Leadership Team



**Ms. Juliet Hull**

**B.Nurse ATI, MBA MGSM**

**Non-executive Director**

- **MBA from the Macquarie Graduate School of Management, and Bachelor of Nursing from the Auckland Technical Institute.**
- **More than 20 years' experience working in Asia and Pacific markets in Healthcare, in sales, Marketing and leadership. Juliet was the General Manager/Country Director for Johnson & Johnson Medical in New Zealand and has held various roles in Johnson & Johnson in Australia and New Zealand since 2012.**



**Dr. Dexter Cheung**

**B. Tech (Hons), M.Eng, PHD**

**Non-executive Director**

- **Experienced medical device engineer and specialist in product research and development. Research and Development Manager of the respiratory humidification division of Fisher & Paykel Healthcare, an ASX/NZX listed healthcare company.**
- **20 Years of experience, Dr. Cheung brings a strong understanding of manufacturing processes and has worked with suppliers and manufacturers across the globe.**
- **Technical background in opto-electronics and expertise in medical device engineering is highly relevant to TruScreen, who's cervical cancer screening device harnesses opto-electronic signatures for screening results.**



# An Experienced Leadership Team



**Martin Dillon**  
**CEO**

- Martin Dillon, the CEO of TruScreen Group Ltd, skilfully managed the company’s listing on the NZX and oversees its strategic vision. With over 30 years of commercial experience, he has engaged with health and regulatory authorities worldwide.
- Martin has held senior executive roles including at CEO and Managing Director level in private and public companies in healthcare, advertising and marketing.



**Mr. Guy Robertson**  
**B. Com (Hons.) CA**  
**CFO & Company Secretary**

- Guy is an experienced finance executive, having held the positions of Director, Company Secretary and Chief Financial Officer of both private and ASX-listed companies in Australia and Hong Kong.
- Guy held senior roles in the Jardine Matheson Group of Companies, including General Manager Finance of Franklins Limited, Chief Operating Officer of Colliers International Asia Pacific and Managing Director (NSW) Jardine Lloyd Thompson.




**Professor Michael Campion**  
**Medical Advisory Committee Chair**

- University of New South Wales graduate (1977), Scientific Program Director of the British Society for Colposcopy and Cervical Pathology (1985 - 1987).
- Victor Bonney Award recipient (London Obstetrics and Gynaecology Society, 1986) for his pivotal research into the role of human papillomaviruses in the causation of cervical cancer.
- Director of the Preinvasive Unit, Gynaecological Cancer Centre, Royal Hospital for Women, Randwick
- Published over 60 academic papers, articles, book and book chapters and presented at numerous scientific congresses.



# The TruScreen Journey



For personal use only

# The TruScreen Technology




- Enabled by AI, TruScreen provides an **accurate, real time** cervical cancer screening solution
- Each TruScreen examination takes **one to two minutes to produce results**, compared to conventional Pap tests which can take days, weeks, or even months in some countries, for a result to be returned.



## How it works

- 1 a pen-like wand covered by a **Single Use Sensor (SUS)** is used to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. It sends and picks up low level **electrical and optical signals** (14 readings per second) from the cervical tissue.



## How it works

2

The TruScreen **Handheld Device (HHD)** then applies an integrated AI-enabled algorithm to analyse these signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological diagnoses.

This identifies the presence of abnormal (cancerous and pre-cancerous) cells in the cervix and provides physicians with real-time results.



- ✓ Clinicians/physicians are able to **immediately plan appropriate patient care**
- ✓ Device has an expected life span of 5–7 years
- ✓ **Disposable SUS is used once per test per patient - ensures there is no chance of cross-infection between patients**
- ✓ The entire patient data collection and analysis is self-checked and controlled. **No tissue sample needs to be taken.** These measures ensure that the results are reliable and consistent, and that the examination is painless and safe
- ✓ **TruScreen has been used on over 1 million women and there has never been a single adverse event reported**



For personal use only

# Why TruScreen?



# Extensive body of clinical evidence

Over 40,000 women in clinical trials to date\*\*\*

Year	Country	Investigator	N
2002	China	Dr Huang Yi	683
2002	China	Dr Wang Ziyao	301
2003	UK/Aus	Prof A. Singer	651
2008	Poland	Dr. Pruski	234
2009	China	Prof Ding Ma	302
2010	China	Dr. He Xiu-Kui	392
2010	China	Prof Fengnian Rong	532
2010	Korea	Dr. Hyeong Soo Lim	292
2011	Poland	Dr. Pruski	293
2011	China	Dr. Li Xia	500
2015	Turkey	Dr. Özgü E	285
2016	China	Dr. LI Pei,	368
2017	Mexico	Dr. Ricardo Lua	521
2018	China	Dr. Huixia Yang	2730
2018-2021	China	54 Hospitals	14,982

Year	Country	Investigator	N
2019	China	Dr. Baojin Wang	315
2019	China	Dr. Wei Zhang	1030
2019	China	Dr. Yanhong Jia	320
2020	China	Dr Kang Yanan	192
2021	China	Prof Chen Fei	974
2021	China	Dr Wei Yingting	458
2022	China	Dr Chen Zhenbo	476
2022	China	Dr Zhu Bo	283
2022	China	Dr Zhao Yuqian	1319
2022	Australia	Dr Jessica Vet	506
2023	China	Dr Luo Lianmei	318
2023	China	Dr Liu Hang	997
2024	China	Dr Yang Yueming	489
2024	China	Dr Fengyi Xiao & Long Sui	1908
2024	Saudi Arabia	Dr S Maqsood and DrM Alhudhud	507

\*\*\*Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II



## COGA Trial (n= 15,661, 2018-2021) <sup>4</sup>

- TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
- TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method
- TruScreen was determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality to cervical cancer
- Also highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-testing. The size of the COGA study, which was TruScreen's largest clinical evaluation to date, lends extra significance to its results and broad conclusions.

TruScreen's  
**sensitivity**  
was well above that for LBC  
(87.5% v's 66.5%), with a high  
degree of statistical  
significance (p<0.001).

The **sensitivity** of TruScreen-hrHPV co-  
testing (carrying out with multiple types  
of screening tests at the same time, as  
opposed to a single type) was higher than  
that of LBC-hrHPV co-testing,  
**98.4% vs 95.9%**  
(statistically significant at p=0.006).

TruScreen's  
**specificity**  
(88.4%) was higher than both  
LBC (86.3%) and hrHPV  
testing (78.3%) (also at  
p<0.001).

# Why TruScreen?

	Truscreen	Liquid Based Cytology (LBC)	HPV DNA
Real time results	✓		
Low infrastructure costs	✓		
Strong clinical results	✓	✓	✓
Objective results	✓		
Low training threshold	✓		
Portable	✓		
No cell or tissue samples taken	✓		



For personal use only

For personal use only

# TruScreen Sales Strategy and Markets



# TruScreen Sales Strategy

- TruScreen focuses on emerging economies such as China, India, Indonesia, Mexico, Uzbekistan, Vietnam and Zimbabwe. Unlike the developed western markets, these countries have no or minimal large-scale cervical cancer screening programs and infrastructure.
- This creates a gap in the market for TruScreen that is not available in the developed market and allows quicker market access from a relative lack of existing competition.
- In contrast to competing products such as cytology and HPV DNA screening TruScreen is 'capital light', not requiring lab infrastructure to be established prior to commencing screening.

## Recurring Revenue Model

- **TruScreen manufactures two devices –**
  - **one made in China for use in China, where locally manufactured products have preferential market access**
  - **one made in Australia for other markets**
- **For each patient screened with the TruScreen device a new disposable Single Use Sensor (SUS) must be used. This creates a recurring revenue model with a consumable sale for each patient screened with TruScreen.**


# Entry into Public Screening Programs

- **TruScreen’s sales to date have been achieved largely through traditional sales of devices and Single Use Sensors to hospitals and clinics. In FY25 these traditional channels made up 99% of sales.**
- **Following the previous success of TruScreen’s use in public screening programs in Zimbabwe, TruScreen is currently targeting public screening programs in Zimbabwe, Vietnam, Uzbekistan Mexico and Eswatini.**
- **These programs have large numbers of enrolled women (e.g Ho Chi Minh City - 260,000 women to be screened over 5 years) and are expected to contribute greater than 20% of total sales in FY26.**
- **An ever increasing percentage of sales is expected from these programs in following years.**



# TruScreen's presence and global markets

For personal use only



NATIONAL MEDICAL PRODUCTS ADMINISTRATION  
国家药品监督管理局



# TruScreen Regulatory Approvals

## Recognized by

- World Health Organisation (WHO)
- UNITAID
- Clinton Health Access Initiative
- Daffodil Foundation - Australia
- China Obstetricians and Gynaecologists Association
- China Society for Colposcopy and Cervical Pathology
- Russia Cervical Cancer Screening Guideline
- Vietnam Hospital Technical List

## International Approvals:

- CE Mark, European Union
- NMPA, China
- TGA, Australia
- MHRA, UK
- SFDA, Saudi Arabia
- Roszdravnadzor, Russia
- COFEPRIS, Mexico
- WAND New Zealand
- Zimbabwe Ministry of Health
- IEAKI Indonesia
- Vietnam Technical List

## International Quality Accreditation:

- ISO 13485
- ISO 60601-1-2
- CE Mark

For personal use only

# TruScreen Highlights

## CY24 - CY25





## TruScreen and Dalton BioScience

### MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton Bioscience

- TruScreen to distribute globally (excluding USA and Canada) via selected distributors DaltonBio HPV related IVD products including DNA tests and Self Sampling.
- DaltonBio to explore opportunities to assist TruScreen's AI enabled real time cervical screening device within its distribution network, notably its 200 Sub-distributors in China and regulatory and distribution partners in South America




NATIONAL MEDICAL PRODUCTS ADMINISTRATION  
国家药品监督管理局





## Key market China, accounting for over 85% of global sales, exceeded budget and is poised for expansion in 6 key provinces


- **Key provinces for growth:** TruScreen's China distributor Beijing Siweixiangtai Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - Guangxi, Jiangsu, Hunan, Zhejiang, Shanghai and Guangdong. These provinces have a combined population of 496 million, and an addressable screening market of approximately 124 million women.
- **TruScreen unaffected by US and China proposed tariff regimes:** TruScreen markets both an Australian and a Made in China device, providing a dual product strategy in the key China market, with preferential market access for China manufactured products
- **SUS Pull Through:** Consumable Single Use Sensor (SUS) pull through per month per device has reached peak of 142 SUS per month per device, an increase of 30 % over 12 months.
- **Software Upgrade:** China's NMPA registration variations have been approved and software upgrade on Chinese devices has commenced. The upgrade will improve user experience for clinicians and extend the device's in-use service interval.



- **Private Sector Expansion:** SWXT targeting of the growing China private health sector including private clinic and Health Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine Hospital sectors.
- **Public Health Insurance:** In addition to having 11 provinces with approved pricing for TruScreen, Beijing has awarded public health insurance reimbursement for eligible TruScreen patients. Shanghai has completed the final round of evaluation for public health insurance reimbursement and once the administrative processes for this are formalised sales are expected to grow rapidly in this province.



*In April 2025 TruScreen and SWXT planned the expansion of TruScreen sales in China. From left to right: Mr Li, partner SWXT, Marty Dillon, CEO TruScreen, Miss Su Siming, Managing Director SWXT, Tony Ho, Chair TruScreen and Mr Wang, SWXT manager of TruScreen business in China*





## TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption in Vietnam picks up pace

- The formal agreement to conduct a 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City was signed in April 2025


Following the signing of a Memorandum of Understanding with the Ho Chi Minh City Public Health Association and Gorton Health Services (Truscreen’s Vietnam distributor) in November, TruScreen has been selected as the primary screening methodology for the capability of its unique, AI-enabled real time cervical cancer screening technology to assist the Government of Vietnam achieve its goal of screening 60% of women aged 30 to 54 for cervical cancer (currently only 25% screened).

- **Public Hospital Adoption**

In January 2025 Professor Michael Campion presented at Tu Duc Hospital in Ho Chi Minh City, leading to 6 major Ho Chi Minh City hospitals agreeing to adopt and install TruScreen.



April 12 2025. TruScreen Chair Tony Ho, President of the Ho Chi Minh City Public Health Association Dr Le Truong Giang and Managing Director of Gorton Health Services Mr An Trang sign the formal agreement to conduct a 260,000 women screening program in Ho Chi Minh City.



NATIONAL MEDICAL PRODUCTS ADMINISTRATION  
国家药品监督管理局






## TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025

India holds one-sixth of the world's population and one woman dies from cervical cancer every eight minutes in the country.

The cervical cancer screening rate is only 2%, and India's National Academy of Medical Sciences (NAMS) has recently set a target of 70% by 2030.

The appointment of Renovate Biologicals now gives TruScreen distribution capability in 3 of the 4 most populous countries in the world - China, India and Indonesia.





## Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025


- **Distributor Appointed:** Following the completion of product registration, TruScreen appointed a new Indonesian medical products distributor PT Mawar Mitra Medika with commercial sales commenced in the world's largest Islamic nation, with a population spread over 14,000 islands. TruScreen offers an ideal solution to providing screening to a geographically dispersed and diverse population.
- **AI presentation by CEO to MOH officials and KOL's.** In December 2024, TruScreen presented to an AI Health webinar organised by Austrade and the Indonesian Ministry of Health. TruScreen was one of only two companies invited to present at this webinar, a recognition of our growing reputation as a leader in AI innovative health technology with a particular relevance to emerging economies.

INDONESIA

96 million  
women of  
screening age\*

✓ TruScreen results and suitability in emerging markets continues to be validated by independent studies and the World Health Organization

- **October 2024** – UNITAID included TruScreen in its technology landscape report “Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer”, the only opto-electrical device included
- **October 2024** - TruScreen selected as a ‘Top 6 Pick’ - one of six global companies, from a cohort of 580 companies, that will have an impact on global women’s health. The evaluation was conducted by Austrian based StartUs Insights.



- **November 2024** – following the UNITAID inclusion, TruScreen were invited to present at the World Health Organisation (WHO) key meeting to further the use of AI technologies for screening of cervical cancer in Edinburgh, and were the only opto-electric tissue differentiating medical device company invited to participate.
- **November 2024** - An Obstetrics and Gynaecology Hospital of Fudan University study (n=1908) concluded that TruScreen optoelectronic real time screening detection accuracy was outperformed liquid-based cytology (LBC) in patients with type 3 cervical transformation zone. The report was published by leading research journal, Germany's Springer Nature
- **July 2024/April 2025** - The preliminary publication in July 2024 of a Saudi Arabia study investigating TruScreen's performance versus pap smears in cervical cancer detection, was peer reviewed and published by globally renowned BMC Women's Health. The study, entitled "Beyond Tradition: Investigating TruScreen's Performance Versus Pap Smear in Cervical Cancer Detection"<sup>1</sup> tested 507 women and was first published on Research Square1 Link on 25 July 2024. Results showed that TruScreen demonstrated: High Sensitivity: TruScreen 83.3%, compared to Pap Smear 66.7% / High Specificity: TruScreen 95%, compared to Pap Smear 98.2%
- **April and May 2025** – TruScreen and the Baylor Foundation Eswatini agree on the validation and initial product training for TruScreen to be used for a pilot program to screen women in Eswatini, formally Swaziland



# TruScreen Outlook: FY26 and beyond



For personal use only



# FY25 Sales (Actual)

NZ\$ 1.71m

# FY26 Sales (Projection)

NZ\$ 2.8m

Projected +64% YOY increase with increased diversification of revenue




This slide contains forward-looking information and should be read in conjunction with the important information on pages 2 – 4 of this presentation



For personal use only

# TruScreen Expected Sales Increase FY26

**NZ\$ 2.8m**



*This slide contains forward-looking information and should be read in conjunction with the important information on pages 2 – 4 of this presentation*



# Growth Strategies



Market expansion to continue with China the key focus



Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total popn 496m



Strengthen China Distribution Capability via Strategic Partnership with Dalton Bio



Strengthen vertical Asian market from Indonesia through China, and capitalise on Indian distribution network



Target Govt and NGO funded programs in Zimbabwe, Vietnam, Mexico and Uzbekistan



Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance and remove barriers to sale

## Growth Strategies (cont.)



Focus on countries with limited or nil cervical screening capability



Expand product portfolio to include Dalton Bio HPV related IVD products DNA tests, including HPV DNA tests and self sampling



Developing strategic partnerships for complementary woman's health services



Reduce SUS and Device COGS and increase margins



Capitalise on global focus on AI enabled cervical cancer technologies – e.g. WHO

# TruScreen Options

## Key Terms:



## Attached Share Option

Subject to Shareholder approval by way of an ordinary resolution at a special meeting of TruScreen shareholders, Eligible Shareholders who participate in the SPP or the Placement will also receive an unlisted option (“Share Option”) with the following rights and liabilities:

*(a) Rights and liabilities attaching to the Options:* Each Share Option issued by the Company will entitle its holder (“Optionholder”) to subscribe for one (1) fully paid ordinary share in the Company (“Share”) on the following terms and conditions.

*(b) Expiry Date:*

- i. The Share Options will expire at 7:00pm New Zealand Time on the date that is one (1) year from the date of issue of the initial shares issued pursuant to the SPP or Placement (as applicable) (“Expiry Date”).
- ii. Any Share Options not validly exercised before the Expiry Date will automatically lapse on the Expiry Date.

*(c) Exercise Price:* The amount payable upon exercise of each Share Option is A\$[0.02] (NZ\$[0.022] (“Exercise Price”).

*(d) Exercise multiples:* The Share Options held by an Optionholder may be exercised in whole or in part. If exercised in part, there is no minimum exercise multiple.

**(e) Exercise Notice:** An Optionholder may exercise their Share Options at any time before they lapse by lodging with the Company:

- i. a written notice of exercise of Share Options specifying the number of Share Options being exercised (“Exercise Notice”); and
- ii. electronic funds transfer for the Exercise Price for the number of Share Options being exercised.

**(f) Effective exercise:** The exercise of any Share Options is only effective on and from the later of:

- i. the date of receipt by the Company of an Exercise Notice for those Share Options; and
- ii. when the Company has received the full amount of the Exercise Price for those Share Options in cleared funds.

**(g) Timing of issue of Shares on exercise:** The Company will issue to the Optionholder, on the last Australasian Business Day of the calendar month following a valid exercise of Share Options in accordance with paragraph (f) above, the number of Shares required under these terms and conditions to be issued in respect of the number of Share Options validly exercised by the Optionholder. The Company will take any necessary steps to ensure that, immediately after the Shares are issued, they are quoted on the ASX or NZX.

***(h) Shares issued on exercise:*** All Shares issued upon the exercise of any Share Options will upon issue rank pari passu in all respects with other Shares.

***(i) Share Options not transferable:*** The Share Options are not transferable.

***(j) Quotation of Share Options:*** The Company will not apply for quotation of the Share Options on ASX or NZX.

***(k) Reorganisation of capital:*** If at any time the issued capital of the Company is reorganised, all rights of an Optionholder are to be changed in a manner consistent with, and to the extent necessary to comply with, the Listing Rules applying to reorganisations of capital at the time of the reorganisation.

***(l) Participation in new issues:*** There are no participation rights or entitlements inherent to the Share Options and the Optionholders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Share Options (unless the relevant Share Options have been validly exercised and the Optionholder has been entered in the register of members of the Company as holding the Shares issued to it on exercise of those Share Options).

***(m) No voting rights:*** The Share Options do not carry any voting rights.

***(n) Change in exercise price:*** Subject to paragraph (k) above, an Option does not confer the right to a change in exercise price or a change in the number of underlying securities over which the Option can be exercised.

*Terms capitalised but otherwise not defined in pages 42 – 44 of this Investor Presentation shall have the meaning given to them in the SPP Booklet released to the market on or about the date of this Investor Presentation.*

# Contact us for more Information



**Martin Dillon**  
CEO

M – +61 449 115 065  
E – [martindillon@truscreen.com](mailto:martindillon@truscreen.com)

TruScreen  
Suite 3.03 18 Orion Rd  
Lane Cove West NSW 2066  
Australia

[www.truscreen.com](http://www.truscreen.com)



**Guy Robertson**  
Chief Financial Officer

M – +61 407 983 270  
E – [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

TruScreen  
Suite 3.03 18 Orion Rd  
Lane Cove West NSW 2066  
Australia

[www.truscreen.com](http://www.truscreen.com)

## References

\*Women aged 15-64 years as detailed in the World Fact Book : <https://www.cia.gov/the-world-factbook/>